<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>Transthyretin cardiac amyloidosis is a progressive disease known to cause heart failure, conduction anomalies, and arrythmias. Due to poor outcomes and mortality from severe cardiomyopathy, prevalence and incident rates are often underreported. As global longevity is increasing and rates of amyloidosis are also increasing, there is a need to improve diagnostic and therapeutic interventions. Previously, symptom management and transplantation were the mainstay of treatment for heart failure symptoms, but studies using RNAi and siRNA technologies have shifted the paradigm of therapeutic strategy in amyloid cardiomyopathy management. Additionally, early detection and clinical monitoring with numerous imaging and non-imaging techniques are being increasingly investigated. Here, we review the epidemiology, pathophysiology, diagnosis, and management of transthyretin amyloid cardiomyopathy.</p>
</abstract>

Transthyretin cardiac amyloidosis is a progressive disease known to cause heart failure, conduction anomalies, and arrythmias. Due to poor outcomes and mortality from severe cardiomyopathy, prevalence and incident rates are often underreported. As global longevity is increasing and rates of amyloidosis are also increasing, there is a need to improve diagnostic and therapeutic interventions. Previously, symptom management and transplantation were the mainstay of treatment for heart failure symptoms, but studies using RNAi and siRNA technologies have shifted the paradigm of therapeutic strategy in amyloid cardiomyopathy management. Additionally, early detection and clinical monitoring with numerous imaging and non-imaging techniques are being increasingly investigated. Here, we review the epidemiology, pathophysiology, diagnosis, and management of transthyretin amyloid cardiomyopathy.

A review of transthyretin cardiac amyloidosis

Department of Advanced Heart Failure and Transplant

Romanian Journal of Internal Medicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

{"article-title":"A review of transthyretin cardiac amyloidosis"}

Transthyretin cardiac amyloidosis is a progressive disease known to cause heart failure, conduction anomalies, and arrythmias. Due to poor outcomes and...

A review of transthyretin cardiac amyloidosis

Publié en ligne: 16 mars 2023

Pages: 28 - 34

Reçu: 06 oct. 2022

DOI: https://doi.org/10.2478/rjim-2022-0018

Mots clés
cardiomyopathy, amyloidosis, heart failure, transplantation

© 2023 Nikita Jhawar et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

A review of transthyretin cardiac amyloidosis

Publié en ligne: 16 mars 2023

Pages: 28 - 34

Reçu: 06 oct. 2022

DOI: https://doi.org/10.2478/rjim-2022-0018

Mots cléscardiomyopathy, amyloidosis, heart failure, transplantation

© 2023 Nikita Jhawar et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Mots clés
cardiomyopathy, amyloidosis, heart failure, transplantation